Physician

Ehab El-Bahesh, M.D.

According to 2025 Medicare claims, Ehab El-Bahesh, M.D. (NPI: 1467689505) practices hematology/oncology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35805-2606.

El-Bahesh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 956 traditional Medicare patients, billed 200,338 HCPCS/CPT codes, and received $3,597,022 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,610 prescription claims across 276 beneficiaries totaling $7,487,334 in drug costs, led by Nubeqa (Darolutamide). DME data shows 93 claims. Open Payments data shows 119 records totaling $38,635. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $464,145 to $3,597,022. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,758 to $7,487,334. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $982 to $3,926.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	440	60,751	$464,145
2017	1,021	255,477	$2,467,678
2018	941	245,339	$3,026,947
2019	923	194,659	$2,652,882
2020	945	286,816	$3,535,816
2021	833	229,604	$3,406,155
2022	978	253,176	$3,712,959
2023	958	251,499	$3,827,761
2024	956	200,338	$3,597,022

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	51	$3,758
2016	68	178	$54,868
2017	183	890	$612,532
2018	173	1,058	$790,485
2019	185	1,048	$1,031,815
2020	219	1,350	$2,044,898
2021	229	1,176	$1,587,417
2022	252	1,118	$2,738,450
2023	266	1,154	$3,739,705
2024	276	1,610	$7,487,334

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	71	$18,384
2018	N/R	76	$9,279
2019	N/R	73	$9,764
2020	N/R	52	$4,096
2021	N/R	44	$4,601
2022	N/R	229	$186,152
2023	N/R	38	$21,787
2024	N/R	93	$26,779

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	434	978	$89
82728	Ferritin (blood protein) level	300	484	$13
80053	Blood test, comprehensive group of blood chemicals	784	1,820	$10
36415	Insertion of needle into vein for collection of blood sample	768	1,840	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	802	1,892	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nubeqa	Darolutamide	112	3,360	$1,485,387
Revlimid	Lenalidomide	49	1,225	$748,579
Tagrisso	Osimertinib Mesylate	44	1,320	$720,121
Xtandi	Enzalutamide	49	1,470	$657,553
Kisqali	Ribociclib Succinate	34	952	$468,378

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$19,163
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	13	$4,285
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$1,495
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$665
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$512

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	116	$22,798	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$15,838	Boehringer Ingelheim Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ehab El-Bahesh, M.D.?

Tedicare shows public-source Medicare data for Ehab El-Bahesh, M.D. (NPI 1467689505), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ehab El-Bahesh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ehab El-Bahesh, M.D.?

Ehab El-Bahesh, M.D. is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Ehab El-Bahesh, M.D. have Open Payments data?

Ehab El-Bahesh, M.D. has 119 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.